Trial Profile
A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Hormone-Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
- 09 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.